Portola Pharmaceuticals, Inc. | TalkMarkets

Latest Posts

Biotech M&A Deal Looks Too Rich For Its Blood

Article By: Lipper Alpha Insight

Wednesday, May 6, 2020 10:46 AM EDT

Alexion Pharmaceuticals (ALXN) is either buying Portola Pharmaceuticals (PTLA) on the cheap at $1.4 billion, or paying a whopping premium – it all depends on your starting date.

In this article: ALXN, PTLA

Read

Wall Street's Top Stories For Monday, Dec 31

Article By: The Fly

Monday, December 31, 2018 5:12 PM EDT

Though December has been a bad month for the market, stocks opened in positive territory on the prospects of progress in the trade negotiations between the U.S. and China. Plus company news updates on Amazon, Disney, Verizon, and more.

In this article: CWH, DIS, VZ, AMZN, HRTX, PTLA, APHA

Read

Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant

Article By: Rod Raynovich

Friday, January 26, 2018 6:44 PM EDT

Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.

In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA

Read

Citi Still Expects FDA Approval For Portola Despite 90 Day Delay

Article By: The Fly

Thursday, December 28, 2017 7:39 AM EDT

After speaking to management, Citi analyst Yigal Nochomovitz expects Portola Pharmaceuticals' AndexXa to be approved on or before the new FDA action date of May 4, 2018.

In this article: PTLA

Read